OBJECTIVES: Low-grade colonic mucosal inflammation has been postulated to have an important role in the pathophysiology of irritable bowel syndrome (IBS). The objectives of this study were (i) to identify serum and tissue-based immunological and neuroendocrine markers associated with mucosal inflammation in male (M) and female (F) patients with non-post-infectious IBS (non-PI-IBS) compared with healthy controls and (ii) to assess possible correlations of such markers with IBS symptoms. METHODS: Sigmoid mucosal biopsies were obtained from 45 Rome II positive IBS patients without a history of PI-IBS (26 F, 35.5% IBS-C, 33.3% IBS-D, 31.1% IBS-A/M) and 41 healthy controls (22 F) in order to measure immunological markers (serum cytokine levels, colonic mucosal mRNA levels of cytokines, mucosal immune cell counts) and neuroendocrine markers associated with mucosal inflammation (corticotropin releasing factor- and neurokinin (NK)-related ligands and receptors, enterochromaffin cells). Symptoms were measured using validated questionnaires. RESULTS: Of all the serum and mucosal cytokines measured, only interleukin-10 (IL-10) mRNA expression showed a group difference, with female, but not male, patients showing lower levels compared with female controls (18.0±2.9 vs. 29.5±4.0, P=0.006). Mucosal mRNA expression of NK-1 receptor was significantly lower (1.15±0.19 vs. 2.66±0.56, P=0.008) in female, but not male, patients compared with healthy controls. No other significant differences were observed. CONCLUSIONS: Immune cell counts and levels of cytokines and neuropeptides that are associated with inflammation were not significantly elevated in the colonic mucosa of non-PI-IBS patients, and did not correlate with symptoms. Thus, these findings do not support that colonic mucosal inflammation consistently has a primary role in these patients. However, the finding of decreased IL-10 mRNA expression may be a possible biomarker of IBS and warrants further investigation.
OBJECTIVES: Low-grade colonic mucosal inflammation has been postulated to have an important role in the pathophysiology of irritable bowel syndrome (IBS). The objectives of this study were (i) to identify serum and tissue-based immunological and neuroendocrine markers associated with mucosal inflammation in male (M) and female (F) patients with non-post-infectious IBS (non-PI-IBS) compared with healthy controls and (ii) to assess possible correlations of such markers with IBS symptoms. METHODS: Sigmoid mucosal biopsies were obtained from 45 Rome II positive IBSpatients without a history of PI-IBS (26 F, 35.5% IBS-C, 33.3% IBS-D, 31.1% IBS-A/M) and 41 healthy controls (22 F) in order to measure immunological markers (serum cytokine levels, colonic mucosal mRNA levels of cytokines, mucosal immune cell counts) and neuroendocrine markers associated with mucosal inflammation (corticotropin releasing factor- and neurokinin (NK)-related ligands and receptors, enterochromaffin cells). Symptoms were measured using validated questionnaires. RESULTS: Of all the serum and mucosal cytokines measured, only interleukin-10 (IL-10) mRNA expression showed a group difference, with female, but not male, patients showing lower levels compared with female controls (18.0±2.9 vs. 29.5±4.0, P=0.006). Mucosal mRNA expression of NK-1 receptor was significantly lower (1.15±0.19 vs. 2.66±0.56, P=0.008) in female, but not male, patients compared with healthy controls. No other significant differences were observed. CONCLUSIONS: Immune cell counts and levels of cytokines and neuropeptides that are associated with inflammation were not significantly elevated in the colonic mucosa of non-PI-IBSpatients, and did not correlate with symptoms. Thus, these findings do not support that colonic mucosal inflammation consistently has a primary role in these patients. However, the finding of decreased IL-10 mRNA expression may be a possible biomarker of IBS and warrants further investigation.
Authors: Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara Journal: Am J Gastroenterol Date: 2009-01-13 Impact factor: 10.864
Authors: Timothy G Dinan; Gerard Clarke; Eamonn M M Quigley; Lucinda V Scott; Fergus Shanahan; John Cryan; John Cooney; P W N Keeling Journal: Am J Gastroenterol Date: 2008-09-10 Impact factor: 10.864
Authors: Stephan C Bischoff; Reiner Mailer; Oliver Pabst; Gisela Weier; Wanda Sedlik; Zhishan Li; Jason J Chen; Dennis L Murphy; Michael D Gershon Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-12-18 Impact factor: 4.052
Authors: L Chang; S Sundaresh; J Elliott; P A Anton; P Baldi; A Licudine; M Mayer; T Vuong; M Hirano; B D Naliboff; V Z Ameen; E A Mayer Journal: Neurogastroenterol Motil Date: 2008-08-05 Impact factor: 3.598
Authors: S Kindt; L Van Oudenhove; D Broekaert; A Kasran; J L Ceuppens; X Bossuyt; B Fischler; J Tack Journal: Neurogastroenterol Motil Date: 2008-12-05 Impact factor: 3.598
Authors: Lena Ohman; Stefan Isaksson; Ann-Charlotte Lindmark; Iris Posserud; P-O Stotzer; Hans Strid; Henrik Sjövall; Magnus Simrén Journal: Am J Gastroenterol Date: 2009-04-14 Impact factor: 10.864
Authors: John Macsharry; Liam O'Mahony; Aine Fanning; Emer Bairead; Graham Sherlock; Jay Tiesman; Andy Fulmer; Barry Kiely; Timothy G Dinan; Fergus Shanahan; Eamonn M M Quigley Journal: Scand J Gastroenterol Date: 2008 Impact factor: 2.423
Authors: Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman Journal: Am J Gastroenterol Date: 2016-06-07 Impact factor: 10.864
Authors: F Bellucci; L Buéno; R Bugianesi; A Crea; V D'Aranno; S Meini; P Santicioli; M Tramontana; C A Maggi Journal: Br J Pharmacol Date: 2016-03-07 Impact factor: 8.739
Authors: Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper Journal: J Gastroenterol Date: 2014-01-17 Impact factor: 7.527